Paleolithic Diet in the Treatment of Diabetes Type 2 in Primary Health Care

This study has been completed.
Sponsor:
Information provided by:
Lund University Hospital
ClinicalTrials.gov Identifier:
NCT00435240
First received: February 13, 2007
Last updated: May 13, 2008
Last verified: May 2008

February 13, 2007
May 13, 2008
January 2005
September 2007   (final data collection date for primary outcome measure)
  • area under the curve for glucose (AUC Glucose0-120) at the oral glucose tolerance test at baseline, 3 months and 6 months
  • area under the curve for insulin (AUC Insulin0-120) at the oral glucose tolerance test at baseline, 3 months and 6 months
  • HbA1C at baseline, 3 months and 6 months
  • weight at baseline, 3 months and 6 months
  • waist circumference at baseline, 3 months and 6 months
Same as current
Complete list of historical versions of study NCT00435240 on ClinicalTrials.gov Archive Site
  • satiation measured on visual semi-analogous scale at food intake during 4 days av 6 weeks and 12 weeks
  • leptin at baseline, 3 months and 6 months
  • fasting plasma glucose at baseline, 3 months and 6 months
  • fasting plasma insulin at baseline, 3 months and 6 months
  • Systolic and diastolic blod pressure at baseline, 3 months and 6 months
  • Blood lipids at baseline, 3 months and 6 months
  • C-reactive protein at baseline, 3 months and 6 months
Same as current
Not Provided
Not Provided
 
Paleolithic Diet in the Treatment of Diabetes Type 2 in Primary Health Care
Not Provided

There is uncertainty about the optimal diet in the prevention and treatment of diabetes type 2. Earlier studies have generally focused on intakes of fat, protein, carbohydrate, fiber, fruit and vegetables. This study is based on another approach which compares foods that were available during human evolution with more recently introduced ones. The basic tenet from evolutionary biology is that if human physiology is less adapted to a relatively recently introduced diet based on agriculture, this could cause disturbances to human physiology and ultimately lead to diseases. Epidemiological studies indicates that diabetes mellitus type 2 is absent or near absent in populations eating a Palaeolithic ("Old Stone Age") diet which is free from food items produced in agriculture or the food industry. Our study hypothesis is that a Palaeolithic diet is better than the standard diabetes diet recommended today in treating diabetes type 2.

Fifteen patients with diabetes type 2 have been randomized to

  1. a Palaeolithic diet based on lean meat, fish, fruit, vegetables, root vegetables, eggs, and nuts
  2. a standard diabetes diet as recommended by national health authorities.

The patients eat the diet they have been randomized to for three months and then switches to the other diet for another three months. The study is conducted in Primary Health Care stations.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Diabetes Mellitus, Type 2
Behavioral: Paleolithic diet
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
13
September 2007
September 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adults with capacity to perform study
  • Diabetes Mellitus Type 2
  • C-peptide > 0
  • HbA1C >5.5
  • Unchanged diabetes treatment during last 3 months
  • Weight and HbA1C varied less than 5% during last 3 months
  • No acute heart disease during last 6 months
  • Unchanged treatment with betablocker last 6 months
  • Unchanged treatment with thyroid hormone substitution last 6 months

Exclusion Criteria:

  • Treatment with insulin
  • Chronic treatment with steroids (not inhaled)
  • Treatment with Waran (anticoagulant cumarin type)
  • Creatinin > 130 micromol/L
  • Elevated liver enzymes (ALAT,ASAT,ALP or GT > 4 X upper reference value)
  • Acute heart disease
  • Changed treatment with betablocker or thyroid hormone substitution
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Sweden
 
NCT00435240
H4 726/2004
Not Provided
Dr Tommy Jönsson, Department of Clinical Sciences, Medical Faculty, Lund University Hospital, Sweden
Lund University Hospital
Not Provided
Principal Investigator: Tommy Jönsson, MD Department of Clinical Sciences, Lund University, Lund Sweden
Lund University Hospital
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP